
Article 1 
In the second column of the Annex to Regulation (EC) No 1356/2004, the words ‘Eli Lilly and Company Limited’ are replaced by the words ‘Elanco GmbH’.
Article 2 
In the second column of the Annex to Regulation (EC) No 1464/2004, the words ‘Eli Lilly and Company Limited’ are replaced by the words ‘Elanco GmbH’.
Article 3 
In the second column of the Annex to Regulation (EC) No 786/2007, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 4 
In the second column of the Annex to Regulation (EC) No 971/2008, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 5 
In the second column of the Annex to Regulation (EU) No 1118/2010, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 6 
In the second column of the Annex to Regulation (EU) No 169/2011, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 7 
In the second column of the Annex to Regulation (EU) No 888/2011 the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 8 
Regulation (EU) No 667/2013 is amended as follows:

((1)) In the title, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’;
((2)) In the second column of the Annex, the words ‘Eli Lilly and Company Ltd’ are replaced by the words ‘Elanco GmbH’.
Article 9 
Monensin sodium, narasin, endo-1,4-beta-mannanase, and diclazuril produced and labelled before the date of entry into force of this Regulation in accordance with the rules applicable before that date may continue to be placed on the market and used until stocks are exhausted.
Article 10 
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 29 January 2019.
For the Commission
The President
Jean-Claude JUNCKER